Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Ho

Dermatology Greenwood Village, CO Medical Doctor

NPI 1497720403 CMS profile 248922

5340 S Quebec St Ste 300, Greenwood Village, CO 80111

Open in the dashboard

General payments

$7,081

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Ho of Greenwood Village, CO is reported in the CMS Open Payments database as having received $7,081 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,076 54
2024 General $1,476 56
2023 General $1,203 53
2022 General $1,407 42
2021 General $709 29
2020 General $373 20
2019 General $836 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Ho
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stephen Ho were reported at $1,076. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stephen Ho Dermatology median Middle half National median
2019 $836 $454 $129–$1,240 $163
2020 $373 $235 $81–$756 $114
2021 $709 $377 $108–$1,108 $132
2022 $1,407 $514 $143–$1,391 $149
2023 $1,203 $607 $159–$1,674 $160
2024 $1,476 $751 $204–$1,903 $164
2025 $1,076 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,577 84 payments
  2. Janssen Biotech, Inc. $647 20 payments
  3. Genzyme Corporation $568 26 payments
  4. Lilly USA, LLC $460 11 payments
  5. Regeneron Healthcare Solutions, Inc. $434 18 payments
  6. Pfizer Inc. $413 22 payments
  7. Sun Pharmaceutical Industries Inc. $411 15 payments
  8. Galderma Laboratories, L.P. $334 9 payments
  9. Incyte Corporation $291 14 payments
  10. UCB, Inc. $277 12 payments
  11. Other $1,669 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,789 286 payments
  2. Education $293 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $796 31 payments
  2. RINVOQ $723 40 payments
  3. TREMFYA $611 18 payments
  4. SKYRIZI Immunology $483 26 payments
  5. DUPIXENT Inflammation And Immunology $319 14 payments
  6. EUCRISA $315 17 payments
  7. OPZELURA $255 12 payments
  8. HUMIRA $229 12 payments
  9. TALTZ $219 9 payments
  10. SKYRIZI Immunology $204 10 payments
  11. Other $3,744 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

460

Median for Dermatology: 534

Drug cost

$11,641

Median for Dermatology: $67,151

Branded share of claims

20.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 43 $2,074
Fluorouracil Generic 28 $1,626
Ciclopirox Ciclopirox Olamine Brand 53 $1,355
Clobetasol Propionate Generic 43 $1,271
Imiquimod Generic 40 $1,250
Doxycycline Hyclate Generic 29 $722
Metronidazole Generic 15 $644
Ketoconazole Generic 40 $621
Ciclopirox Generic 11 $501
Triamcinolone Acetonide Generic 85 $471

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$169,198

Of which drugs: $12,652

Medicare patients

621

Average age 75

Services billed

13,126

198 women, 423 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 43%
Ischemic heart disease 27%
Chronic kidney disease 17%
Cancer 17%
Diabetes 16%
Atrial fibrillation 16%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 37 9,600 $12,540
Injection, fluorouracil, 500 mg J9190 Office 13 15 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $189
  • Regeneron Healthcare Solutions, Inc. $167
$355 — —
TREMFYA
  • Janssen Biotech, Inc. $251
$251 — —
RINVOQ
  • AbbVie, Inc. $159
$159 — —
OPZELURA
  • Incyte Corporation $107
$107 — —
SKYRIZI
  • AbbVie, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record